Protein Aggregation as an Active Driver of Physiological Aging

40 concepts10 papers1 proposal

For decades, protein aggregation was viewed primarily as a hallmark of specific neurodegenerative diseases like Alzheimer's or Parkinson's. In the context of normal, healthy aging, the appearance of protein clumps was often dismissed as a passive byproduct of cellular wear-and-tear.

However, a growing body of evidence turns this paradigm on its head. Recent research demonstrates that protein aggregation is an early, active driver of physiological aging across diverse tissues. Rather than being inert garbage, these aggregates disrupt cellular stoichiometry, alter metabolic pathways, and trigger chronic inflammation. Understanding why and how these aggregates form in healthy tissue reveals new therapeutic strategies to extend healthspan by directly dismantling them.

The Trigger: Early Collapse of Cellular Clearance

Why do proteins begin to aggregate in tissues free of classical disease mutations? The root cause lies in an early, systemic decline in the cell's protein quality control machinery—specifically the proteasome and the lysosome.

In Reduced proteasome activity in the aging brain results in ribosome stoichiometry loss and aggregation, Erika Kelmer Sacramento et al. showed that a drop in proteasome activity is one of the earliest measurable events in brain aging, occurring well before widespread protein aggregation becomes visible. Crucially, this decline directly predicts organismal lifespan. When proteasome activity dips, the cell can no longer maintain the precise balance of protein concentrations required for multi-protein complexes. This leads to a loss of stoichiometry in vital machinery like ribosomes, causing individual subunits to destabilize and clump together.

A parallel breakdown occurs in the lysosomal pathway. The lysosomal protein TMEM106B has emerged as a key player in this process. In Age-dependent formation of TMEM106B amyloid filaments in human brains, Manuel Schweighauser et al. discovered that TMEM106B spontaneously forms amyloid filaments in the brains of older individuals who have no diagnosed neurological conditions. This indicates that amyloid formation is a normal, age-dependent physiological event rather than an exclusively pathological one.

As these aggregates grow, they create a destructive feedback loop. Mehtap Bacioglu et al. demonstrated in Cleaved TMEM106B forms amyloid aggregates in central and peripheral nervous systems that cleaved TMEM106B aggregates accumulate within endosomal and lysosomal compartments across both the central and peripheral nervous systems. By physically congesting these waste-disposal organelles, the aggregates further cripple the cell's ability to clear misfolded proteins, accelerating systemic decline.

This structural vulnerability is tightly linked to genetic factors. As reviewed by Haishan Jiao et al. in TMEM106B aggregation in neurodegenerative diseases: linking genetics to function, genetic variations that elevate TMEM106B levels drive its aggregation into amyloid fibrils, disrupting lysosomal function and bridging normal aging with neurodegenerative pathology.

The Mechanism: Turning Normal Proteins into Amyloid Traps

The threat of aggregation is not confined to damaged or mutated proteins. In a healthy young organism, newly synthesized proteins are carefully chaperoned into their correct shapes. As the organism ages, however, even normal, intrinsically stable proteins fall victim to the changing cellular environment.

Using C. elegans as a model, Chaolie Huang et al. established in Intrinsically aggregation-prone proteins form amyloid-like aggregates and contribute to tissue aging in Caenorhabditis elegans that age-dependent aggregates are composed heavily of newly synthesized, wild-type proteins that rapidly adopt amyloid-like structures. This reveals that physiological aging is characterized by a systemic failure to maintain protein solubility. Once these amyloid-like structures form, they act as physical and biochemical traps, actively contributing to functional tissue decline rather than existing as harmless bystanders.

The Downstream Toll: Metabolic Failure and Inflammation

How do these structural alterations translate into the systemic symptoms of aging? The answer lies in two distinct downstream mechanisms: metabolic reprogramming and chronic inflammation.

Metabolic Reprogramming

Proteins that aggregate often lose their primary biological functions, paralyzing essential cellular pathways. In PKM2 aggregation drives metabolism reprograming during aging process, Juntao Bie et al. discovered that the glycolytic enzyme PKM2 progressively aggregates during normal aging. Because PKM2 is a cornerstone of cellular energy production, its aggregation forces a profound reprogramming of cellular metabolism. This metabolic shift directly triggers cellular senescence and drives organismal aging phenotypes.

Chronic Inflammation

In addition to loss-of-function effects, aging proteins undergo spontaneous chemical modifications that introduce toxic gains of function. One such modification is deamidation, which generates an "isoDGR" structural motif. In Immunotherapy targeting <scp>isoDGR</scp> ‐protein damage extends lifespan in a mouse model of protein deamidation, the authors demonstrated that the accumulation of isoDGR acts as a primary driver of chronic, age-related inflammation.

The physiological consequences of this modification are tissue-specific and severe. Pazhanichamy Kalailingam et al. expanded on this in Immunotherapeutic targeting of aging‐associated isoDGR motif in chronic lung inflammation, showing that isoDGR-modified proteins accumulate extensively in aging lung tissue. The modified motif binds directly to integrins on immune cells, triggering a persistent inflammatory cascade that causes edema, hypoxemia, and age-related lung disease.

Complex Interplay and Environmental Modifiers

This internal structural decline is further modulated by complex molecular networks and external environmental factors. For instance, R. Loch et al. noted in Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases that the intricate molecular cross-talk between Apolipoprotein E (ApoE) isoforms and various amyloid proteins plays an underappreciated role in modulating aggregation kinetics.

Meanwhile, the body's microbiota interacts directly with modified proteins. In The Interaction between Human Microbes and Advanced Glycation End Products: The Role of Klebsiella X15 on Advanced Glycation End Products’ Degradation, Aiying Shi et al. demonstrated that the gut bacterium Klebsiella X15 can degrade protein-bound advanced glycation end products (AGEs) to use as a nitrogen source, illustrating how the microbiome might influence the systemic burden of age-related protein damage.

Therapeutic Reversal: Proving Causality by Clearing Aggregates

The ultimate test of whether protein aggregation causes aging—rather than merely correlating with it—is whether dissolving these structures can reverse the aging process. Recent interventions targeting these aggregates have successfully proven this causal link.

To address metabolic decline, Juntao Bie et al. identified small-molecule compounds capable of specifically dissolving PKM2 aggregates. In vivo administration of these compounds cleared the aggregates, reversed markers of cellular senescence, improved physical function, and significantly extended the lifespan of aged mice.

Similarly, targeted immunotherapies have been deployed to combat aggregate-induced inflammation. The antibody therapies developed by Pazhanichamy Kalailingam et al. to target the isoDGR motif successfully cleared damaged proteins from circulation and tissues. In doing so, these therapies suppressed chronic inflammation, alleviated age-related lung pathologies like edema, and extended both healthspan and lifespan in animal models.

By shifting the focus from rare genetic diseases to universal physiological mechanisms, this research direction demonstrates that maintaining the integrity of the proteome is not just a way to prevent neurodegeneration—it is a direct pathway to slowing the biological clock.

History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_early_proteasome_dysfunction_in_aging_610cc753,
  title = {early proteasome dysfunction in aging},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/early-proteasome-dysfunction-in-aging/rdr_610cc75361694dd8be95ded293dba9bd},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}

This exact version (version 1, frozen text):

@misc{lacuna_early_proteasome_dysfunction_in_aging_610cc753_v1,
  title = {early proteasome dysfunction in aging},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/early-proteasome-dysfunction-in-aging/rdr_610cc75361694dd8be95ded293dba9bd/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-21},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake